Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s disease

References

• Jankovic J, Tan EK. Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795–798.
   PubMed Web of Science ®Google Scholar
• Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114(5):2283–01.
   PubMedGoogle Scholar
• Abbott A. Levodopa: the story so far. Nature. 2010;466(7310):S6–S7.
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–08.
   PubMed Web of Science ®Google Scholar
• Cilia R, Cereda E, Akpalu A, et al. Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa. Brain. 2020;143(8):2490–2491.
   PubMed Web of Science ®Google Scholar
• Morgan JC, Currie LJ, Harrison MB, et al. Mortality in levodopa-treated Parkinson’s disease. Parkinsons Dis. 2014;2014. https://doi.org/10.1155/2014/426976
   Google Scholar
• Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson’s disease: Olmsted County project. Neurology. 1993;43(10):1918–1926.
   PubMedGoogle Scholar
• Kalilani L, Friesen D, Boudiaf N, et al. The characteristics and treatment patterns of patients with Parkinson’s disease in the United States and United Kingdom: a retrospective cohort study. In: Fonoff ET editor. PLoS One. Vol. 14. 2019. pp. e0225723.
   Google Scholar
• Lenka A, Padmakumar C, Pal PK. Treatment of older Parkinson’s disease. Int. Rev. Neurobiol. 2017;132:381–405.
   PubMed Web of Science ®Google Scholar
• Surathi P, Kamble N, Bhalsing KS, et al. Prescribing pattern for Parkinson’s disease in Indian community before referral to tertiary center. Can J Neurol Sci/J Can des Sci Neurol. 2017;44(6):705–710.
   Google Scholar
• Young C, Phillips R, Ebenezer L, et al. Management of Parkinson’s disease during pregnancy. Literature Review and Multidisciplinary Input. Mov Disord Clin Pract. 2020;7(4):419–430.
   PubMedGoogle Scholar
• Kurlan R. “Levodopa phobia”: a new iatrogenic cause of disability in Parkinson disease. Neurology. 2005;64(5):923–924.
   PubMed Web of Science ®Google Scholar
• Titova N, Levin O, Katunina E, et al. ‘Levodopa Phobia’: a review of a not uncommon and consequential phenomenon. Npj Park Dis. 2018;4(1):31.
   PubMedGoogle Scholar
• Espay AJ, Lang AE. Common myths in the use of Levodopa in Parkinson disease. JAMA Neurol. 2017;74(6):633–634.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary. Neurology. 2021;97(20):942–957.
   PubMed Web of Science ®Google Scholar
• Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized delayed-start trial of Levodopa in Parkinson’s disease. N Engl J Med. 2019;380(4):315–324.
   PubMed Web of Science ®Google Scholar
• Delea TE, Thomas SK, Hagiwara M. the association between adherence to Levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with parkinson’s disease. CNS Drugs. 2011;25(1):53–66.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Hallett M, Okun MS, et al. Medical treatment of the motor features of Parkinson disease. In: Jankovic J, Hallett M, Okun MS, et al., editors. Princ pract mov disord. 3rd editio Philadelphia: Elsevier; 2021. p. 164–203.e14.
   Google Scholar
• Malek N, Grosset DG. Medication adherence in patients with Parkinson’s disease. CNS Drugs. 2015;29(1):47–53.
   PubMed Web of Science ®Google Scholar
• Johnsrud M, Richards K, Arcona S, et al. An assessment of Parkinson’s disease medication treatment patterns in the Medicaid population. Clin Park Relat Disord. 2021; 5: 100109.
   PubMedGoogle Scholar
• Cilia R, Laguna J, Cassani E, et al. Daily intake of Mucuna pruriens in advanced Parkinson’s disease: a 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord. 2018;49:60–66.
   PubMedGoogle Scholar
• Rijntjes M. Knowing your beans in Parkinson’s disease: a critical assessment of current knowledge about different beans and their compounds in the treatment of Parkinson’s disease and in animal models. Parkinsons Dis. 2019;2019:1–9.
   Google Scholar
• Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet. 2002;41(4):261–309.
   PubMed Web of Science ®Google Scholar
• Mena MA, Casarejos MJ, Solano RM, et al. Half a century of L-DOPA. Curr Top Med Chem. 2009;9(10):880–893.
   PubMedGoogle Scholar
• Gervas JJ, Muradas V, Bazan E, et al. Effects of 3-OM-dopa on monoarnine metabolism in rat brain. Neurology. 1983;33(3):278.
   PubMedGoogle Scholar
• Müller T. Catechol-O-Methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75(2):157–174.
   PubMed Web of Science ®Google Scholar
• Greenwood J, Pham H, Rey J. Opicapone: a third generation COMT inhibitor. 2021;Clin Park Relat Disord. 4:100083.
   PubMedGoogle Scholar
• Robakis D, Fahn S. Defining the role of the monoamine oxidase-b inhibitors for Parkinson’s disease. CNS Drugs. 2015;29(6):433–441.
   PubMedGoogle Scholar
• Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered Levodopa in Parkinsonian patients. Clin Neuropharmacol. 1987;10(6):527–537.
   PubMed Web of Science ®Google Scholar
• Fernandez N, Garcia JJ, Diez MJ, et al. Effects of dietary factors on levodopa pharmacokinetics. Expert Opin Drug Metab Toxicol. 2010;6(5):633–642.
   PubMed Web of Science ®Google Scholar
• Boelens Keun JT, Arnoldussen IA, Vriend C, et al. Dietary approaches to improve efficacy and control side effects of Levodopa therapy in Parkinson’s disease: a systematic review. Adv Nutr. 2021;12(6):2265–2287.
   PubMedGoogle Scholar
• Robertson D, Higginson I, Macklin B, et al. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol. 1991;31(4):413–417.
   PubMed Web of Science ®Google Scholar
• Tsui JK, Ross S, Poulin K, et al. The effect of dietary protein on the efficacy of L-dopa: a double-blind study. Neurology. 1989;39(4):549–552.
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Martinelli P, et al. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled is release in parkinsonian patients. Eur J Clin Pharmacol. 1998;54(4):303–308.
   PubMedGoogle Scholar
• Gershanik OS. Improving l -dopa therapy: the development of enzyme inhibitors. Mov Disord. 2015;30(1):103–113.
   PubMed Web of Science ®Google Scholar
• Tourtellotte WW, Syndulko K, Potvin AR, et al. Increased ratio of carbidopa to Levodopa in treatment of Parkinson’s disease. Arch Neurol. 1980;37(11):723–726.
   PubMedGoogle Scholar
• Brod LS, Aldred JL, Nutt JG. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson’s disease. Mov Disord. 2012;27(6):750–753.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kuoppamäki M, Vahteristo M, et al. Increased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial. Neurology. 2019;92(13):e1487–e96.
   PubMed Web of Science ®Google Scholar
• Iwaki H, Nishikawa N, Nagai M, et al. Pharmacokinetics of levodopa/benserazide versus levodopa/carbidopa in healthy subjects and patients with Parkinson’s disease. Neurol Clin Neurosci. 2015;3:68–73.
   Web of Science ®Google Scholar
• Baba Y, Futamura A, Kinno R, et al. The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson’s disease: a retrospective cohort study. J Neurol Sci. 2022;437:120263.
   PubMedGoogle Scholar
• Pfeiffer RF, Isaacson SH, Pahwa R. Clinical implications of gastric complications on levodopa treatment in Parkinson’s disease. Parkinsonism Relat Disord. 2020;76:63–71. Internet.
   PubMed Web of Science ®Google Scholar
• Soliman H, Coffin B, Gourcerol G. Gastroparesis in Parkinson disease: pathophysiology, and clinical management. Brain Sci. 2021;11:831.
   PubMedGoogle Scholar
• Palma J-A, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018;33:372–390.
   PubMed Web of Science ®Google Scholar
• Heetun ZS, Quigley EMM. Gastroparesis and Parkinson’s disease: a systematic review. Parkinsonism Relat Disord. 2012;18:433–440.
   PubMed Web of Science ®Google Scholar
• Venkitachalam A, Lazarescu A, Suchowersky O. Enteral Levodopa therapy in advanced Parkinson’s disease with Gastroparesis. Mov Disord Clin Pract. 2015;2:321–322.
   PubMedGoogle Scholar
• Camilleri M, Atieh J. New developments in prokinetic therapy for gastric motility disorders. Front Pharmacol. 2021;12. DOI:https://doi.org/10.3389/fphar.2021.711500
   Google Scholar
• Lertxundi U, Echaburu SD, Soraluce A, et al. Domperidone in Parkinson’s disease: a perilous arrhythmogenic or the gold standard? Curr Drug Saf. 2013;8:63–68.
   PubMedGoogle Scholar
• Arnold G, Schwarz J, Macher C, et al. Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients — a double blind study. Parkinsonism Relat Disord. 1997;3:191–193.
   PubMedGoogle Scholar
• Metman LV, Hoff J, Mouradian MM, et al. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord. 1994;9:463–465.
   PubMed Web of Science ®Google Scholar
• Kurth MC, Tetrad JW, Irwin I, et al. Oral levodopa/carbidopa solution versus tablets in Parkinson’s patients with severe fluctuations: a pilot study. Neurology. 1993;43:1036–1039.
   PubMedGoogle Scholar
• Pfeiffer R, Ebadi M. On the mechanism of the nullification of CNS effects of l-DOPA by pyridoxine in parkinsonian patients. J Neurochem. 1972;19:2175–2181.
   PubMedGoogle Scholar
• Knudsen K, Krogh K, Østergaard K, et al. Constipation in Parkinson’s disease: subjective symptoms, objective markers, and new perspectives. Mov Disord. 2017;32:94–95.
   PubMed Web of Science ®Google Scholar
• Astarloa R, Mena MA, Sánchez V, et al. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol. 1992;15:375–380.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Sakakibara R, Kishi M, et al. Constipation triggered the malignant syndrome in Parkinson’s disease. Neurol Sci. 2012;33:347–350.
   PubMed Web of Science ®Google Scholar
• Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord. 2013;28:1241–1249.
   PubMed Web of Science ®Google Scholar
• Li X, Feng X, Jiang Z, et al. Association of small intestinal bacterial overgrowth with Parkinson’s disease: a systematic review and meta-analysis. Gut Pathog. 2021;13:25.
   PubMedGoogle Scholar
• Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson’s disease. Npj Parkinson’s Disease. 2022;8(1):56.
   PubMed Web of Science ®Google Scholar
• Cooper MK, Brock DG, McDaniel CM. Interaction Between Levodopa and Enteral Nutrition. Ann Pharmacother. 2008;42:439–442.
   PubMedGoogle Scholar
• Beckwith MC, Beckwith MC, Feddema SS, Barton RG, et al. A guide to drug therapy in patients with enteral feeding tubes: dosage form selection and administration methods. Hospital Pharmacy. 2004;39(3):225–237.
   Google Scholar
• LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18(2):145–154.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–149.
   PubMed Web of Science ®Google Scholar
• Lang AE, Rodriguez RL, Boyd JT, et al. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016;31(4):538–546.
   PubMed Web of Science ®Google Scholar
• Freire‐Alvarez E, Kurča E, Lopez Manzanares L, et al. Levodopa-Carbidopa intestinal gel reduces dyskinesia in Parkinson’s disease in a randomized trial. Mov Disord. 2021;36(11):2490–2501.
   Google Scholar
• Poewe W, Stocchi F, Arkadir D, et al. Subcutaneous Levodopa infusion for Parkinson’s disease: 1 -year data from the open-label beyond Study. Mov Disord. 2021;36(11):2687–2692.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Espay AJ, Stocchi F, et al. Continuous subcutaneous Levodopa delivery for Parkinson’s disease: a randomized study. J Parkinsons Dis. 2021;11(1):177–186.
   PubMedGoogle Scholar
• Giladi N, Gurevich T, Djaldetti R, et al. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson’s disease and motor response fluctuations: a randomized, placebo-controlled phase 2 study. Parkinsonism Relat Disord. 2021;91:139–145.
   PubMed Web of Science ®Google Scholar
• Li J, Cox DRA, Muralidharan V, et al. Small intestine enterostomy for the intraoperative delivery of levodopa in a patient with severe Parkinson’s disease. BMJ Case Rep. 2020;13(12). DOI:https://doi.org/10.1136/bcr-2020-240367.
   Google Scholar
• Mittur A, Gupta S, Modi NB. Pharmacokinetics of rytary®, an extended-release capsule formulation of carbidopa–Levodopa. Clin Pharmacokinet. 2017;56(9):999–14.
   PubMedGoogle Scholar
• Fahn S. Adverse effects of Levodopa in Parkinson’s disease. In: D.b C, editor. Drugs treat park dis handb exp pharmacol. Berlin Hiedelberg: Springer; 1989. p. 385–389.
   Google Scholar
• Singer C. Adverse effects in the treatment of Parkinson’s disease. Expert Rev Neurother. 2002;2(1):105–118.
   PubMedGoogle Scholar
• Saranza G, Lang AE. Levodopa challenge test: indications, protocol, and guide. J Neurol. 2021;268(9):923.2–924.
   Google Scholar
• Wilde MI, Markham A. Ondansetron: a review of its pharmacology and preliminary clinical findings in novel applications. Drugs. 1996;52(5):773–794.
   PubMed Web of Science ®Google Scholar
• Fraschini G, Ciociola A, Esparza L, et al. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol. 1991;9(7):1268–1274.
   PubMedGoogle Scholar
• Calne DB, Brennan J, Spiers ASD, et al. Hypotension caused by l-dopa. BMJ. 1970;1(5694):474–475.
   PubMedGoogle Scholar
• Noack C, Schroeder C, Heusser K, et al. Cardiovascular effects of levodopa in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:815–818.
   PubMed Web of Science ®Google Scholar
• Coon EA. Autonomic Dysfunction in the synucleinopathies. Semin Neurol. 2020;40(5):492–01.
   PubMedGoogle Scholar
• Bouhaddi M, Vuillier F, Fortrat JO, et al. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson’s disease: involvement of l-dopa therapy. Auton Neurosci. 2004;116(1–2):278–8.
   Google Scholar
• Ha AD, Brown CH, York MK, et al. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson’s disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011;17(8):157–174.
   Google Scholar
• Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584–589.
   PubMed Web of Science ®Google Scholar
• Jost WH, Altmann C, Fiesel T, et al. Influence of levodopa on orthostatic hypotension in Parkinson’s disease. Neurol Neurochir Pol. 2020. DOI:https://doi.org/10.5603/PJNNS.a2020.0019.
   Google Scholar
• Goldstein DS, Eldadah BA, Holmes C, et al. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension. Hypertension. 2005;46(6):1333–1339.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Fabre N, et al. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(5):501–505.
   PubMed Web of Science ®Google Scholar
• Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson’s disease. Parkinsonism Relat Disord. 2009;15:S224–32.
   PubMed Web of Science ®Google Scholar
• Cutsforth-Gregory JK, Low PA. Neurogenic orthostatic hypotension in Parkinson disease: a primer. Neurol Ther. 2019;8(2):307–324.
   PubMedGoogle Scholar
• Beaulieu-Boire I, Lang AE. Behavioral effects of levodopa. Mov Disord. 2015;30(1):372–390.
   Google Scholar
• Contin M, Provini F, Martinelli P, et al. Excessive daytime Sleepiness and Levodopa in Parkinson’s disease: polygraphic, placebo-controlled monitoring. Clin Neuropharmacol. 2003;26(3):115–118.
   PubMedGoogle Scholar
• Andreu N, Chalé -J-J, Senard J-M, et al. L-dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol. 1999;22(1):15–3.
   PubMedGoogle Scholar
• Müller T, Benz S, Przuntek H. Choice reaction time after levodopa challenge in parkinsonian patients. J Neurol Sci. 2000;181(1–2):98–03.
   PubMedGoogle Scholar
• Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of sleep medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(9):1895–45.
   PubMed Web of Science ®Google Scholar
• Lenka A, Gomathinayagam V, Bahroo L. Approach to the management of psychosis in Parkinson’s disease. Annals of Movement Disorders. 2019;2(3):83–90.
   Google Scholar
• Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review. Mov Disord. 2019;34(2):180–198.
   PubMed Web of Science ®Google Scholar